Antiproliferative effect of two novel COX-2 inhibitors on human keratinocytes.

  title={Antiproliferative effect of two novel COX-2 inhibitors on human keratinocytes.},
  author={Claudia Sticozzi and Giuseppe Belmonte and Franco Cervellati and Angela Di Capua and Emanuela Maioli and Andrea Cappelli and Antonio Giordani and Mariangela Biava and Maurizio Anzini and Giuseppe Valacchi},
  journal={European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences},
  volume={49 2},
  • C. SticozziG. Belmonte G. Valacchi
  • Published 13 May 2013
  • Biology
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Figures from this paper

Anti-Psoriasis Effect of Diclofenac and Celecoxib Using the Tail Model for Psoriasis

Celecoxib 2% had the greatest percentual drug activity and is a promising substance for the anti-psoriasis topical treatment and along with the COX-2 inhibition, celecoxib might have an anti-PSoriasis effect by other independent mechanisms.

1,5-Diarylpyrroles as potent antitubercular and anti-inflammatory agents

This minireview surveys the work of our research group directed toward finding novel antimycobacterial and anti-inflammatory drugs. Many active compounds were found with a common 1,5-diarylpyrrole

5‐hydroxytryptophan attenuates imiquimod‐induced psoriasiform dermatitis probably through inhibition of IL‐17A production and keratinocyte activation

5(OH)Trp can inhibit imiquimod‐induced psoriasiform dermatitis in mice and inhibit activation in keratinocytes and splenocytes, and reduce the cumulative scores, epidermal thickness and ki‐67 expression in the skin.

A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity.



Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation.

The 2,3-dimethyl-5-(4-methylsulfonylphenyl)-4-phenyl-4-isoxazoline (3), which possesses an electron rich central 5-membered isoxazole ring, could serve as a lead compound to develop novel drugs to treat prostate cancer.

Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

Evidence is provided, for the first time, that a specific COX-2 inhibitor, celecoxib, possesses strong chemopreventive activity against colon carcinogenesis.

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

Questions that remain to be addressed are whether this hazard extends to all or some of the traditional NSAIDs; whether adjuvant therapies, such as low-dose aspirin, will mitigate the hazard and if so, at what cost; whether COX-2 inhibitors result in cardiovascular risk transformation during chronic dosing; and how to identify individuals most likely to benefit or suffer from such drugs in the future.

Cox-2 inhibitors and the risk of cardiovascular thrombotic events.

The available evidence regarding cardiovascular (CV) safety data and contemporary recommendations for prescribing of COX-2-selective NSAIDs are summarized.

Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.

The issues gained with these classes of compounds represent, nowadays, a potent stimulus for a further enlargement of the NSAIDs family.

Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity.

The potential anti-inflammatory and antinociceptive activities of compounds 7a, 8a, and 8d were evaluated in vivo, where they showed a very good activity against both carrageenan-induced hyperalgesia and edema in the rat paw test.

Chemopreventive activity of celecoxib, a specific cyclooxygenase‐2 inhibitor, and indomethacin against ultraviolet light–induced skin carcinogenesis

The dramatic protective effects of celecoxib suggests that specific COX‐2 inhibitors may offer a way to safely reduce the risk of skin cancer in humans.

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

This review presents the recently emerged direct non-COX-2 targets of celecoxib and their proposed role in mediating this drug's antitumour effects.

In vitro and In vivo Effects and Mechanisms of Celecoxib-Induced Growth Inhibition of Human Hepatocellular Carcinoma Cells

The present study showed that celecoxib causes COX-2-dependent and COX2-independent growth inhibition of hepatocellular carcinoma cells and xenografts by decreased retinoblastoma phosphorylation and DP1/E2F1 complex; increased activation of caspase-3 and caspasing-9; and increased expression of proliferator-activated receptor γ.